DB900

	Lead Identification	Candidate Selection Proof of Principle	Pre-Clinical Development	Phase 1	Phase 2a
Development Phase

Product/Technology Name: DB900

Condition/Disease Targeted: Type 2 Diabetes

Product Development: DB900 is a series of compounds which are PPARg/a/d agonists for the treatment of type 2 diabetes.  This compound activates genes involved in the metabolism of sugars and fats thereby improving the body’s ability to regulate blood sugar.  A clinical candidate will be selected from a number of strong lead compounds.  These compounds have the potential to raise good HDL cholesterol, lower bad LDL cholesterol and lower triglycerides with potential greater efficacy than DB959 as well as the potential to deliver weight loss.  This program is currently not being resourced.  Development will be re-initiated when sufficient additional funding is secured.